Have a personal or library account? Click to login

Evaluation of platelet aggregation and platelet derived microparticles in acute leukemia patients

Open Access
|Jun 2014

References

  1. 1. Rassi F El, Arellano M. Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol. 2013 Aug 12;7:181-97. DOI: 10.4137/CMO.S852810.4137/CMO.S8528374809023997579
  2. 2. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer. 2006 January 30;94(2):200-2. DOI: 10.1038/ sj.bjc.660294510.1038/sj.bjc.6602945236111616421591
  3. 3. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005 Sep;3(9):1985-92. DOI: 10.1111/j.1538-7836.2005.01467.x10.1111/j.1538-7836.2005.01467.x16102104
  4. 4. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol. 2012 Nov;24(6):702-10. DOI: 10.1097/ CCO.0b013e328359233110.1097/CCO.0b013e328359233123014188
  5. 5. Franchini M, Frattini F, Crestani S, Bonfanti C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013 Feb;39(1):94-100. DOI: 10.1055/s-0032-133115410.1055/s-0032-133115423247655
  6. 6. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009 113(17):3911-17. DOI: 10.1182/ blood-2008-08-17574510.1182/blood-2008-08-175745267312019088376
  7. 7. Qian X, Wen-Jun L. Platelet Changes in Acute Leukemia. Cell Biochem Biophys. 2013 Dec;67(3):1473-9. DOI: 10.1007/s12013-013-9648-y10.1007/s12013-013-9648-y23703663
  8. 8. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol. 2009 Mar;22(1):153-63. DOI: 10.1016/j. beha.2008.12.007
  9. 9. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009 Aug;102(2):248-57. DOI: 10.1160/TH09-03-019210.1160/TH09-03-019219652875
  10. 10. Foss B, Bruserud O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost. 2008 Jan;99(1):27-37. DOI: 10.1160/TH07-04-024010.1160/TH07-04-024018217131
  11. 11. Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS, O’Leary J, et al. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med. 2013 August;2(4):564-70. DOI: 10.1002/ cam4.8610.1002/cam4.86379929124156029
  12. 12. Costache A, Avram SI, Cernucan A, Barbu D, Angelescu S, Mut Popescu D, et al. What about microparticles? Perspectives and practical aspects. Rev Romana Med Lab. 2013;21(1):9-15. DOI: 10.2478/rrlm-2013-001310.2478/rrlm-2013-0013
  13. 13. Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011 Jan;105(1):14-20. DOI: 10.1160/TH10-03-018710.1160/TH10-03-0187
  14. 14. Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat- George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013Jun;11(Suppl 1):24-35. DOI: 10.1111/jth.1226810.1111/jth.12268
  15. 15. Bucciarelli P, Martinelli I, Artoni A, Passamonti SM, Previtali E, Merati G et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res. 2012 May;129(5):591-7. DOI: 10.1016/j.thromres.2011.08.02010.1016/j.thromres.2011.08.020
  16. 16. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011 May;127(5):473-7. DOI: 10.1016/j.thromres.2011.01.00210.1016/j.thromres.2011.01.002
  17. 17. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010 Sep;126(3):238-42. DOI: 10.1016/j.thromres.2010.06.02510.1016/j.thromres.2010.06.025
  18. 18. Tan X, Shi J, Fu Y, Gao C, Yang X, Li J et al. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemst. 2013 Jun;109(6):1025-32. DOI: 10.1160/TH12-11-081110.1160/TH12-11-0811
  19. 19. Siljander PR. Platelet-derived microparticles - an updated perspective. Thromb Res. 2011 Jan;127(Suppl 2):S30-3. DOI: 10.1016/S0049-3848(10)70152-310.1016/S0049-3848(10)70152-3
  20. 20. Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am Soc Hematol Educ Program. 2007:151-7. DOI: 10.1182/asheducation-2007.1.15110.1182/asheducation-2007.1.15118024623
  21. 21. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006Nov;91(11):1530-7.
  22. 22. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004 Jul;18(3):153-67. DOI: 10.1016/j. tmrv.2004.03.003
  23. 23. Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.J Thromb Haemost. 2011 Nov;9(11):2302-10.DOI: 10.1111/j.1538-7836.2011.04506.x10.1111/j.1538-7836.2011.04506.x321001521920014
  24. 24. Robier C, Neubauer M, Sternad H, Quehenberger F, Rainer F, Neumeister P. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry. Thromb Res. 2010 Sep;126(3):232-7.DOI: 10.1016/j.thromres.2010.06.01410.1016/j.thromres.2010.06.01420630570
  25. 25. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies.Hematology Am Soc Hematol Educ Program. 2007:165-71. DOI: 10.1182/asheducation-2007.1.16510.1182/asheducation-2007.1.16518024625
  26. 26. Nadir Y, Katz T, Sarig G, Hoffman R, Oliven A, Rowe JM, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica. 2005Nov;90(11):1549-56.
  27. 27. Crespo-Solis E. Thrombosis and acute leukemia. Hematology. 2012 Apr;17(Suppl 1):S169-73. DOI: 10.117 9/102453312X13336169156852 10.1179/102453312X1333616915685222507812
DOI: https://doi.org/10.2478/rrlm-2014-0015 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 199 - 207
Submitted on: Jan 7, 2014
Accepted on: Apr 17, 2014
Published on: Jun 21, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2014 Andra Costache, Silvana Angelescu, Doina Barbu, Elena Popescu, Delia Ileana Mut Popescu, Anca Roxana Lupu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.